Search Result

Results for "

pharmacodynamics

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Akt (1) Aminopeptidase (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (2) Antibiotic (2) Apical Sodium-Dependent Bile Acid Transporter (3) ATP Synthase (1) Bacterial (3) Bcl-2 Family (1) Beta-secretase (1) Caspase (1) CDK (2) DNA/RNA Synthesis (1) Dopamine Receptor (5) EGFR (1) Endogenous Metabolite (5) Estrogen Receptor/ERR (1) Factor Xa (1) FAK (1) Histamine Receptor (3) Histone Methyltransferase (1) HSV (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (5) Insulin Receptor (1) Interleukin Related (3) IRE1 (1) Isotope-Labeled Compounds (2) JAK (2) Liposome (1) Melanocortin Receptor (1) mTOR (1) Na+/K+ ATPase (1) Orexin Receptor (OX Receptor) (1) PI3K (1) Potassium Channel (2) PROTACs (1) Sodium Channel (1) Thrombin (1) TNF Receptor (3) Tryptophan Hydroxylase (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (6) Endocrinology (4) Infection (9) Inflammation/Immunology (8) Metabolic Disease (7) Neurological Disease (11)

By Targets:

Adrenergic Receptor (2)

Akt (1)

Aminopeptidase (1)

Anaplastic lymphoma kinase (ALK) (1)

Androgen Receptor (2)

Antibiotic (2)

Apical Sodium-Dependent Bile Acid Transporter (3)

ATP Synthase (1)

Bacterial (3)

Bcl-2 Family (1)

Beta-secretase (1)

Caspase (1)

CDK (2)

DNA/RNA Synthesis (1)

Dopamine Receptor (5)

EGFR (1)

Endogenous Metabolite (5)

Estrogen Receptor/ERR (1)

Factor Xa (1)

FAK (1)

Histamine Receptor (3)

Histone Methyltransferase (1)

HSV (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Influenza Virus (5)

Insulin Receptor (1)

Interleukin Related (3)

IRE1 (1)

Isotope-Labeled Compounds (2)

JAK (2)

Liposome (1)

Melanocortin Receptor (1)

mTOR (1)

Na+/K+ ATPase (1)

Orexin Receptor (OX Receptor) (1)

PI3K (1)

Potassium Channel (2)

PROTACs (1)

Sodium Channel (1)

Thrombin (1)

TNF Receptor (3)

Tryptophan Hydroxylase (1)

By Research Areas:

Cancer (16)

Cardiovascular Disease (6)

Endocrinology (4)

Infection (9)

Inflammation/Immunology (8)

Metabolic Disease (7)

Neurological Disease (11)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-157014

TPT-004	Tryptophan Hydroxylase	Cancer
TPT-004 is a TPH inhibitor. TPT-004 has superior pharmacokinetic and pharmacodynamic properties. TPT-004 also has good efficacy in preclinical models of peripheral serotonin attenuation and colorectal tumor growth .

HY-70002AS

N-desmethyl Enzalutamide-d6 N-desmethyl MDV 3100-d₆	Androgen Receptor	Cancer
N-desmethyl Enzalutamide-d₆ is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1].

HY-B0377

Famotidine 4 Publications Verification MK-208	Histamine Receptor	Metabolic Disease Endocrinology Cancer
Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease
Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes .

HY-12883A

PF-05198007	Sodium Channel	Neurological Disease
PF-05198007 is a potent, orally active and selective arylsulfonamide Na_v1.7 inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .

HY-18353

mTOR inhibitor-3 3 Publications Verification	mTOR	Cancer
mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

HY-113468A

3-O-Methyldopa 3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA	Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-143747

Cap-dependent endonuclease-IN-5	Influenza Virus	Infection
Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .

HY-160251

3-HC-Gluc (3'R,5k'S)-trans-3'-Hydroxycotinine glucuronide	Others	Others
3-HC-Gluc ((3’R,5k’s)-trans-3’ -Hydroxycotinine glucuronide) The trans-structure of 3-HC, the main metabolite of nicotine .

HY-70002A

N-desmethyl Enzalutamide N-desmethyl MDV 3100	Androgen Receptor	Cancer
N-desmethyl Enzalutamide is the active metabolite of Enzalutamide.N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide .

HY-A0147

Grepafloxacin OPC-17116; dl-Grepafloxacin	Antibiotic Bacterial	Infection
Grepafloxacin (OPC-17116) is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin has high tissue penetration and a promising pharmacodynamic profile .

HY-136933

Gitoxin	Na+/K+ ATPase	Cardiovascular Disease
Gitoxin, a Na ⁺/K ⁺-ATPase inhibitor, usually appears as a result of metabolic degradation of Digitoxin, is just the hydroxyl (ZOH) group close to the C-17β position, which changes the pharmacokinetics and pharmacodynamics of these substances considerably .

HY-B0377R

Famotidine (Standard)	Histamine Receptor	Metabolic Disease Endocrinology Cancer
Famotidine (Standard) is the analytical standard of Famotidine. This product is intended for research and analytical applications. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-10787

Ximelagatran 1 Publications Verification H 376/95	Thrombin	Cardiovascular Disease
Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics .

HY-A0147A

Grepafloxacin hydrochloride OPC-17116 hydrochloride; dl-Grepafloxacin hydrochloride	Antibiotic Bacterial	Infection
Grepafloxacin (OPC-17116) hydrochloride is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin hydrochloride has high tissue penetration and a promising pharmacodynamic profile .

HY-B0377S

Famotidine-13C,d3	Isotope-Labeled Compounds Histamine Receptor	Metabolic Disease Endocrinology
Famotidine- ¹³C,d₃ is the ¹³C- and deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-101560

Linrodostat 4 Publications Verification BMS-986205; ONO-7701	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
Linrodostat (BMS-986205) is a selective and irreversible indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC₅₀ value of 1.1 nM in IDO1-HEK293 cells. Linrodostat is well tolerated with potent pharmacodynamic activity in advanced cancers .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-113468AS

3-O-Methyldopa-d3 3-Methoxy-L-tyrosine-d₃; 3-O-Methyl-L-DOPA-d₃	Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa-d₃ is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .

HY-18030A

CEP-28122 mesylate salt	Anaplastic lymphoma kinase (ALK)	Cancer
CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC₅₀ value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity .

HY-N8265

Abyssinone V	HSV DNA/RNA Synthesis ATP Synthase	Infection
Abyssinone V is a prenylated flavonoid with predicted anti-viral activity. Abyssinone V can be isolated from the stem bark of Erythrina melanacantha. Abyssinone V possesses good pharmacodynamics properties. Abyssinone V is predicted to be antivirals including anti-herpes (HSV) agent, with mechanisms comprising inhibition of polymerase, ATPase and membrane integrity .

HY-19517

R1663	Others	Cardiovascular Disease
R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .

HY-113468AS1

3-O-Methyldopa-d3 hydrate 3-Methoxy-L-tyrosine-d₃ hydrate; 3-O-Methyl-L-DOPA-d₃ hydrate	Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-161672

G-5758	Liposome IRE1	Cancer
G-5758 is an orally available IRE1α inhibitor with an IC₅₀ of 38 nM for XBP1s. G-5758 is well tolerated in multiple myeloma models (KMS-11) at oral doses up to 500 mg/kg in rats. G-5758 exhibits pharmacodynamics comparable to that of induced IRE1 knockdown .

HY-109052

Atabecestat JNJ-54861911	Beta-secretase	Neurological Disease
Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment .

HY-132296

GSK215	FAK PROTACs	Cancer
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC₅₀ of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .

HY-118374

AM-9635	PI3K Akt	Inflammation/Immunology
AM-9635 is a selective PI3Kδ inhibitor with oral bioavailability, good in vitro and in vivo activity and pharmacodynamic properties. AM-9635 inhibits PI3Kδ-dependent B cell receptor-mediated AKT phosphorylation and suppresses the production of specific IgG and IgM antibodies in rats immunized with Aplysia leocyanin (KLH).

HY-136805

Kv1.5-IN-1	Others	Neurological Disease
Kv1.5-IN-1 is a Kv1.5 channel inhibitor. Its target selectivity and pharmacodynamic effects were evaluated in an in vitro rat model. After the introduction of a methoxy group at the R5 position, Kv1.5-IN-1 showed inhibitory potency similar to that of the unsubstituted compound. Its IC50 value for hKv1.5 channels was 0.51 μM. Kv1.5-IN-1 exhibited a high degree of selectivity, nearly 2,600 times higher than compound Ik and 300 times higher than compound IId, indicating that it may be a safe inhibitor. Due to its good pharmacological behavior, Kv1.5-IN-1 deserves further pharmacodynamic and pharmacokinetic evaluation. These properties make Kv1.5-IN-1 a potential Kv1.5 channel inhibitor that may have application prospects in the treatment of related diseases.

HY-D1460

Fluorescein Di-β-D-Glucuronide	Bacterial	Infection
Fluorescein Di-β-D-Glucuronide, a fluorescent probe, can be utilized to non-invasively image the intestinal bacterial β-glucuronidase activity in nude mice. Fluorescein Di-β-D-Glucuronide-based imaging reveals the in vitro and in vivo activity of intestinal bacterial β-glucuronidase, which would facilitate pharmacodynamic studies of specific bacterial β-glucuronidase inhibitors in animal studies .

HY-W401531S

(R)-3-O-Methyldopa-d3	Dopamine Receptor Endogenous Metabolite	Neurological Disease
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride	Dopamine Receptor Endogenous Metabolite	Neurological Disease
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-161349

LTA4H-IN-4	Aminopeptidase	Inflammation/Immunology
LTA4H-IN-4 (compound 3) is an orally active LTA4H inhibitor. The IC₅₀ value of LTA4H-IN-4 for hERG is 156 μM. LTA4H-IN-4 can be used in inflammation related studies .

HY-103196

Sotalol	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-B0437

Sotalol hydrochloride 2 Publications Verification MJ 1999	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for Tyk2 JH2 and an IC₅₀ value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-143744

Cap-dependent endonuclease-IN-3	Influenza Virus	Infection
Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .

HY-143743

Cap-dependent endonuclease-IN-2	Influenza Virus	Infection
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .

HY-143755

Cap-dependent endonuclease-IN-9	Influenza Virus	Infection
Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .

HY-135495

AM-0466	Others	Inflammation/Immunology
AM-0466 is a sodium channel inhibitor with nanomolar levels of NaV1.7 inhibitory activity. AM-0466 exhibits potent pharmacodynamic activity in a NaV1.7-dependent histamine-induced itch model. AM-0466 also showed significant analgesic effects in capsaicin-induced pain models. After optimizing its pharmacokinetic properties, AM-0466 was advanced into in vivo targeting and efficacy models for testing .

HY-143757

Cap-dependent endonuclease-IN-10	Influenza Virus	Infection
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .

HY-139920

Oritinib SH-1028	EGFR	Cancer
Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFR ^WT, EGFR ^L858R, EGFR ^L861Q, EGFR ^L858R/T790M, EGFR ^d746-750 and EGFR ^{d746-750/T790M} kinases, with IC₅₀s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively .

HY-10900

TCS 1102	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
TCS 1102 is a potent, dual orexin receptor antagonist, with Ki values of 0.2 nM and 3 nM for OX2 and OX1 receptors, respectively. TCS 1102 demonstrates excellent blood-brain barrier penetrability and moderate bioavailability in rats .

HY-155406

Estrogen receptor modulator 10	Estrogen Receptor/ERR Caspase Bcl-2 Family	Cancer
Estrogen receptor modulator 10 (compound G-5b) is an Estrogen receptor (ER) antagonist (IC₅₀=6.7 nM) and degrader (DC₅₀=0.4 nM). Estrogen receptor modulator 10 can induce apoptosis. Estrogen receptor modulator 10 can block cells at the G1/G0 phase. Estrogen receptor modulator 10 can be used in cancer studies .

HY-126242S

Tyk2-IN-7	JAK	Inflammation/Immunology
Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-133031A

CSV0C018875 hydrochloride	Histone Methyltransferase	Others
CSV0C018875 hydrochloride is a G9a (EHMT2) inhibitor that inhibits G9a activity. CSV0C018875 can effectively inhibit G9a activity in both enzyme and cell-based assays, and its toxicity is much lower than that of the known G9a inhibitor BIX-01294. CSV0C018875 binds tightly to the active site cavity of G9a, thereby improving the binding firmness and prolonging the residence time of the compound, further enhancing the inhibitory effect of G9a. CSV0C018875 has the potential to improve its ADME (absorption, distribution, metabolism and excretion) and pharmacodynamic properties through further optimization .

HY-15790

Elobixibat A 3309; AZD 7806	Apical Sodium-Dependent Bile Acid Transporter Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC₅₀ value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

HY-15790R

Elobixibat (Standard)	Apical Sodium-Dependent Bile Acid Transporter Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology
Elobixibat (Standard) is the analytical standard of Elobixibat. This product is intended for research and analytical applications. Elobixibat is a potent ileal bile acid transporter (IBAT) inhibitor with IC₅₀ values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT.

HY-15790H

(S)-Elobixibat (S)-A 3309; (S)-AZD 7806	Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology
(S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

Cat. No.	Product Name	Type

HY-D1460

Fluorescein Di-β-D-Glucuronide

Fluorescent Dyes/Probes

Fluorescein Di-β-D-Glucuronide, a fluorescent probe, can be utilized to non-invasively image the intestinal bacterial β-glucuronidase activity in nude mice. Fluorescein Di-β-D-Glucuronide-based imaging reveals the in vitro and in vivo activity of intestinal bacterial β-glucuronidase, which would facilitate pharmacodynamic studies of specific bacterial β-glucuronidase inhibitors in animal studies .

Cat. No.	Product Name	Target	Research Area

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease
Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113468A

3-O-Methyldopa 3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA	Structural Classification Monophenols Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-136933

Gitoxin	Digitalis purpurea Linn. Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Scrophulariaceae Plants Disease Research Fields Steroids	Na+/K+ ATPase
Gitoxin, a Na ⁺/K ⁺-ATPase inhibitor, usually appears as a result of metabolic degradation of Digitoxin, is just the hydroxyl (ZOH) group close to the C-17β position, which changes the pharmacokinetics and pharmacodynamics of these substances considerably .

HY-N8265

Abyssinone V	Structural Classification Flavonoids Leguminosae Flavonones Source classification Erythrina melanacantha Taub. ex Harms Plants	HSV DNA/RNA Synthesis ATP Synthase
Abyssinone V is a prenylated flavonoid with predicted anti-viral activity. Abyssinone V can be isolated from the stem bark of Erythrina melanacantha. Abyssinone V possesses good pharmacodynamics properties. Abyssinone V is predicted to be antivirals including anti-herpes (HSV) agent, with mechanisms comprising inhibition of polymerase, ATPase and membrane integrity .

Cat. No.	Product Name	Chemical Structure

HY-70002AS

N-desmethyl Enzalutamide-d6

N-desmethyl Enzalutamide-d₆ is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1].

HY-113468AS

3-O-Methyldopa-d3
3-O-Methyldopa-d₃ is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-B0377S

Famotidine-13C,d3
Famotidine- ¹³C,d₃ is the ¹³C- and deuterium labeled Famotidine. Famotidine (MK-208) is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.

HY-113468AS1

3-O-Methyldopa-d3 hydrate
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-W401531S

(R)-3-O-Methyldopa-d3
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

pharmacodynamics

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products